Stock Market News
Ergomed expects earnings below market consensus despite top line growth
Pharmaceutical services and drug development company Ergomed announced on Monday that it expects its adjusted earnings to be lower than the market consensus.
Despite forecasts for full-year top line growth of 21% to £47m, Ergomed said in a statement that foreign exchange losses related to assets and liabilities would see its bottom line fall £900,000 short of the market consensus.
Revenue growth was driven by a 68% jump in sales at its Drug Safety & Medical Information services arm, a part of the company's service business, while the overall backlog of contracted future work stood at £88m.
Stephen Stamp, Chief Executive Officer of Ergomed, said: "2017 has been a year of exceptional growth and clinical success and it is unfortunate that these late adjustments have just come to light. We believe that our re-focused strategy to take leadership positions in pharmacovigilance and orphan drug development services will take us to the next level. Recent investment in systems will support that growth, most of which remains in front of us."
The company also forecast research and development costs to be £0.3m higher than market consensus after the faster than anticipated completion of the PeproStat Phase II trial.
The Guildford-based company will release its final results on 28 March.
As of 1052 GMT, Ergomed's shares were down 7.14% at 194.00p.
Despite forecasts for full-year top line growth of 21% to £47m, Ergomed said in a statement that foreign exchange losses related to assets and liabilities would see its bottom line fall £900,000 short of the market consensus.
Revenue growth was driven by a 68% jump in sales at its Drug Safety & Medical Information services arm, a part of the company's service business, while the overall backlog of contracted future work stood at £88m.
Stephen Stamp, Chief Executive Officer of Ergomed, said: "2017 has been a year of exceptional growth and clinical success and it is unfortunate that these late adjustments have just come to light. We believe that our re-focused strategy to take leadership positions in pharmacovigilance and orphan drug development services will take us to the next level. Recent investment in systems will support that growth, most of which remains in front of us."
The company also forecast research and development costs to be £0.3m higher than market consensus after the faster than anticipated completion of the PeproStat Phase II trial.
The Guildford-based company will release its final results on 28 March.
As of 1052 GMT, Ergomed's shares were down 7.14% at 194.00p.
Related share prices |
---|
Ergomed (ERGO) share price |
Stock News headlines are gathered from financial news sources around the web. Views and opinions on each item are from their respective authors and website. They are not opinions of LiveCharts.co.uk
Get a free widget for your website with our latest headlines.
You can now add our live prices and new headlines to your website.The news widget features quotes for Oil prices, spot Gold price and Indices plus a choice of news channel for healines.
Top Shares pages
- Share price quotes
- Share charts
- Share watch list
- Company Results Calendar
- Top Large UK Shares
- UK Market Sectors
- Stock market news
- Company news
- Share tips
- A-Z company search
More share features
POPULAR Share Prices
- Royal Mail share price
- Lloyds share price
- HSBC share price
- Barclays share price
- Prudential share price
- Santander share price
- NEXT share price
- Diageo share price
- BP share price
- Vodafone share price
- British Airways
- Centrica share price
- Tesco share price
- Taylor Wimpey Share Price
- National Grid
- GKP Share Price
- Marks and Spencer
- Rolls Royce
- Rio Tinto
- THG Share Price
- Aviva Share Price
- Boil Share price
- Easyjet Share Price
- Genedrive Share Price
- SSE Share Price
- IAG Share Price
- Boohoo share price
- HE1 share price
- AVCT share price
- BOOM share price